KPTI Karyopharm Therapeutics
- 1.380
- +0.280+25.45%
- 1.400
- +0.020+1.43%
Karyopharm Therapeutics News
Karyopharm Therapeutics | SC TO-C: Written communication relating to an issuer or third party tender offer
Karyopharm Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Paulson Richard A.
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Paulson Richard A.
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rangwala Reshma
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Poulton Stuart
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mason Michael
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mano Michael
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Cheng Sohanya Roshan
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Paulson Richard A.
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mano Michael
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Mason Michael
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Poulton Stuart
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Rangwala Reshma
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Cheng Sohanya Roshan
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Paulson Richard A.
Karyopharm Therapeutics | 10-K: Annual report
Karyopharm Therapeutics | 8-K: Current report
Karyopharm Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Poulton Stuart
Karyopharm Therapeutics | 8-K: Current report
Analysis
Price Target
No Data
